Business Wire

Neeva Brings Responsible, Citation-Backed AI Powered Search to Europe

13.2.2023 14:00:00 EET | Business Wire | Press release

Share

Advert and tracker-free search engine Neeva has today launched NeevaAI in Europe, which harnesses the power of artificial intelligence (AI) to deliver an experience that combines the best of large language models such as ChatGPT with the authority and timeliness of search.

Following a successful beta launch in the US in December 2022, NeevaAI is available to Free Basic and Premium users across the world from today. NeevaAI will be launching its English Language version in the UK and Canada, as well as local language versions in Germany, France and Spain.

NeevaAI provides a synthesised single answer with linked sources pulled together from the most relevant sites for a query, allowing users to determine the authenticity and reliability of the cited sources. The feature offers current information by crawling hundreds of millions of pages a day and serving from its independent index of billions of pages. By combining AI with Neeva's in-house search stack that eschews ads and advertisers, results are fast, timely, bias-free and relevant.

Real-time summaries backed by sources

Unlike other AI search offerings, NeevaAI offers current information to the user by interrogating a page, understanding its contents and incoming links to determine whether the page is useful and authoritative and cite the information source. NeevaAI does this in real time as the web changes, which is vital in our fast paced world.

In a feature unique to Neeva, NeevaAI also provides citation cards, in which a search query returns a visual search result with machine learning summaries from all the top results and swipeable cards highlighting authoritative information about the researched topic. The cards also suggest important research questions for the searcher.

Neeva Founder and CEO, Sridhar Ramaswamy comments: “AI is already beginning to make search one of the first and most clearly disrupted industries. NeevaAI leverages in-house LLMs and refined training models with its full system search stack to bring authentic real time AI search to the everyones. Our goal has been to responsibly integrate AI and provide authoritative answers that you can trust.”

Support for publishers in a post-ChatGPT world

Publishers and content creators stand to be greatly impacted by certain AI search models. AI will fundamentally shift individuals’ relationship to finding and consuming information. For publishers, this should be canary in the coal mine, and failing to adapt to this new reality could prove catastrophic for their businesses.

Nowhere is the threat more immediate than in search. As search engines become answer engines, publisher content will get sucked into the AI bots and served back to users without attribution or links. Without links embedded in the AI answer, users won’t find their way to a publisher’s website, effectively choking off the referral traffic pipeline. Significant drops in referral traffic will lead to material impacts on ad revenue especially at a time when most publishers are fighting just to stay afloat. To make matters worse, that same content will also be used to further train large language models (LLMs) exacerbating the publisher’s dilemma.

Neeva is committed to helping publishers leverage AI and LLMs to re-take ownership of the relationships with their users. Neeva is working to help publishers integrate fluent AI search natively in their websites allowing users to discover and consume content seamlessly. Moreover, to support publishers, whose referral traffic is now at greater risk from AI answer bots, Neeva has committed 20% of its topline revenue to content creator and publisher partners when their content is used to directly answer a Neeva customer’s query.

Since launching in the US in 2021, and Europe in late 2022, Neeva has amassed nearly 2 million users. It has built one of the largest independent search stacks crawling hundreds of millions of pages a day and an index of billions. By combining AI with Neeva’s in-house search stack, NeevaAI’s results are lightning fast, timely, and relevant.

ENDS

About Neeva

Neeva is the world’s first ads-free, private subscription search engine powered by AI. Neeva focuses entirely on the consumer, delivering only real, high quality, trustworthy results. Neeva is leading a new AI frontier by leveraging in-house LLMs and refined training models with our full system search stack to bring authentic real-time AI search to everyone. Neeva blocks third-party website trackers, and will never sell or share customer data with anyone, especially advertisers. Neeva also makes it easy to search within personal email accounts, calendars, and cloud storage platforms surfacing the most important information from the same familiar search box. The company was founded by former executives from Google and YouTube. Learn more and start searching today at neeva.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Contact details
press@neeva.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye